PL2461812T3 - Kompozycja do leczenia mukowiscydozy - Google Patents

Kompozycja do leczenia mukowiscydozy

Info

Publication number
PL2461812T3
PL2461812T3 PL10739941T PL10739941T PL2461812T3 PL 2461812 T3 PL2461812 T3 PL 2461812T3 PL 10739941 T PL10739941 T PL 10739941T PL 10739941 T PL10739941 T PL 10739941T PL 2461812 T3 PL2461812 T3 PL 2461812T3
Authority
PL
Poland
Prior art keywords
treatment
composition
cystic fibrosis
cystic
fibrosis
Prior art date
Application number
PL10739941T
Other languages
English (en)
Inventor
Michael Freissmuth
Xaver Koenig
Christina Gloeckel
Original Assignee
Scipharm Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scipharm Sarl filed Critical Scipharm Sarl
Publication of PL2461812T3 publication Critical patent/PL2461812T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL10739941T 2009-08-07 2010-08-05 Kompozycja do leczenia mukowiscydozy PL2461812T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09167491 2009-08-07
PCT/EP2010/061428 WO2011015630A1 (en) 2009-08-07 2010-08-05 Composition for the treatment of cystic fibrosis
EP10739941.2A EP2461812B1 (en) 2009-08-07 2010-08-05 Composition for the treatment of cystic fibrosis

Publications (1)

Publication Number Publication Date
PL2461812T3 true PL2461812T3 (pl) 2014-12-31

Family

ID=41382119

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10739941T PL2461812T3 (pl) 2009-08-07 2010-08-05 Kompozycja do leczenia mukowiscydozy

Country Status (26)

Country Link
US (2) US20120184622A1 (pl)
EP (1) EP2461812B1 (pl)
JP (1) JP5877787B2 (pl)
KR (1) KR101729800B1 (pl)
CN (1) CN102548559B (pl)
AU (1) AU2010280684B2 (pl)
BR (1) BR112012002578B8 (pl)
CA (1) CA2770066C (pl)
CL (1) CL2012000319A1 (pl)
CY (1) CY1114983T1 (pl)
DK (1) DK2461812T3 (pl)
EA (1) EA023720B1 (pl)
ES (1) ES2451790T3 (pl)
GT (1) GT201200038A (pl)
HK (1) HK1165293A1 (pl)
HN (1) HN2012000297A (pl)
HR (1) HRP20140277T1 (pl)
IL (1) IL217899B (pl)
PL (1) PL2461812T3 (pl)
PT (1) PT2461812E (pl)
RS (1) RS53234B (pl)
SG (1) SG178315A1 (pl)
SI (1) SI2461812T1 (pl)
SM (1) SMT201400057B (pl)
WO (1) WO2011015630A1 (pl)
ZA (1) ZA201200790B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
DK2663313T3 (en) * 2011-01-13 2018-11-26 Scipharm S A R L PROCEDURE FOR IMPROVING ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS
SI2672957T1 (sl) * 2011-02-07 2017-03-31 Scipharm Sarl Nova sestava za zdravljenje cistične fibroze
JP6542128B2 (ja) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド トレプロスチニルのプロドラッグ
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2754388T3 (es) 2013-03-15 2020-04-17 Mannkind Corp Composiciones y métodos de dicetopiperazina microcristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2927788C (en) 2013-10-25 2022-09-06 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
WO2016081658A1 (en) 2014-11-18 2016-05-26 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
WO2017192993A1 (en) 2016-05-05 2017-11-09 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
EP3515430A1 (en) 2016-09-26 2019-07-31 United Therapeutics Corporation Treprostinil prodrugs
CA3138530A1 (en) 2019-04-29 2020-11-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
EP4017588A1 (en) 2019-08-23 2022-06-29 United Therapeutics Corporation Treprostinil prodrugs
CN115916212A (zh) 2020-04-17 2023-04-04 联合治疗公司 曲前列尼尔用于治疗间质性肺病
US11793780B2 (en) 2020-06-09 2023-10-24 United Therapeutics Corporation Prodrugs of treprosiinil
EP4259121A1 (en) 2020-12-14 2023-10-18 United Therapeutics Corporation Methods of treating disease with treprostinil prodrugs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041210A1 (fr) * 1997-03-14 1998-09-24 Toray Industries, Inc. Preparation de derive de prostaglandine i a liberation prolongee
US20010006979A1 (en) * 1998-07-08 2001-07-05 Richard Stratton Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
JP4786866B2 (ja) * 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
EP2792353B1 (en) * 2003-05-22 2018-02-28 United Therapeutics Corporation Polymorph of Treprostinil diethanolamine salt
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
ATE551059T1 (de) * 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
CN101410119B (zh) * 2006-02-03 2012-03-07 埃科特莱茵单一股份公司 依前列醇制剂及其制备方法
WO2008098196A1 (en) * 2007-02-09 2008-08-14 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma

Also Published As

Publication number Publication date
BR112012002578B1 (pt) 2021-01-12
EA023720B1 (ru) 2016-07-29
US20120184622A1 (en) 2012-07-19
GT201200038A (es) 2015-01-16
SMT201400057B (it) 2014-07-07
CA2770066C (en) 2018-10-23
ZA201200790B (en) 2013-05-29
US10086001B2 (en) 2018-10-02
ES2451790T3 (es) 2014-03-28
US20160175319A1 (en) 2016-06-23
KR101729800B1 (ko) 2017-04-24
DK2461812T3 (da) 2014-04-07
BR112012002578A2 (pt) 2016-03-15
AU2010280684B2 (en) 2016-07-28
CN102548559A (zh) 2012-07-04
IL217899A0 (en) 2012-03-29
HK1165293A1 (en) 2012-10-05
EP2461812B1 (en) 2014-01-01
SG178315A1 (en) 2012-03-29
JP2013501032A (ja) 2013-01-10
CL2012000319A1 (es) 2012-09-14
HRP20140277T1 (hr) 2014-04-25
WO2011015630A1 (en) 2011-02-10
CA2770066A1 (en) 2011-02-10
AU2010280684A1 (en) 2012-02-23
JP5877787B2 (ja) 2016-03-08
CN102548559B (zh) 2013-12-25
RS53234B (en) 2014-08-29
IL217899B (en) 2018-05-31
SI2461812T1 (sl) 2014-05-30
HN2012000297A (es) 2015-05-18
PT2461812E (pt) 2014-04-07
EA201200253A1 (ru) 2012-07-30
CY1114983T1 (el) 2016-12-14
BR112012002578B8 (pt) 2021-05-25
EP2461812A1 (en) 2012-06-13
KR20120056819A (ko) 2012-06-04

Similar Documents

Publication Publication Date Title
HK1165293A1 (en) Composition for the treatment of cystic fibrosis
IL216800A (en) Preparation for the treatment of dry eye syndrome
HK1143315A1 (en) Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
IL227738B (en) A new compound for the treatment of cystic fibrosis
GB0921075D0 (en) Novel combination of the therapeutic agents
IL210997A0 (en) Compositions for the treatment of mrsa and uses thereof
GB0800145D0 (en) Skincare treatment
EP2404592A4 (en) HAIR TREATMENT COMPOSITION
IL210290A0 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
GB0619500D0 (en) Treatment of fibrosis
IL245995B (en) Prophylactic or medical agent for fibrosis
SG10201408508YA (en) Combination composition useful for treating cardiovascular diseases
ZA201105125B (en) Hair treatment composition
PL2323625T3 (pl) Nowa kompozycja do leczenia pigmentacji wybroczynowych
GB0723100D0 (en) Treatment of HFnEF
ZA201201116B (en) Hair treatment composition
PL2263454T3 (pl) Kompozycja uzdatniająca
EP2490704A4 (en) THERAPEUTIC COMPOSITION
EP2436385A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST LUNG FIBROSIS
GB201000499D0 (en) Treatment of cystic fibrosis
GB201000571D0 (en) Treatment of cystic fibrosis
GB0911577D0 (en) Compositions for the treatment of dry eye
GB0809319D0 (en) The treatment of puritus
GB0821381D0 (en) Compositions for the treatment of dry eye
IL210519A0 (en) Anti-phthiraptera treatment compositions